Conversations with Oncology Investigators: Bridging the Gap between Research and Patient Care
Interview with Mark Robson, MD
Interview with Ian E Krop, MD, PhD
Track 1:
Case: A 68-year-old woman with ER/PR-positive, HER2-negative, moderately differentiated IDC and 5 of 20 positive axillary nodes
Track 2:
PALLAS: An ongoing Phase III trial evaluating the addition of palbociclib to adjuvant endocrine therapy for hormone receptor-positive, HER2-negative early BC
Track 3:
Role of the 21-gene Recurrence Score® (RS) in the neoadjuvant setting
Track 4:
Comparison of the 21-gene RS versus the 70-gene assay to determine benefit from chemotherapy in patients with ER-positive BC
Track 5:
Updated ASCO clinical practice guidelines on the use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive BC
Track 6:
MINDACT trial: Utility of the 70-gene assay in selecting patients with BC and 1 to 3 positive nodes for adjuvant chemotherapy
Track 7:
ABC trials: TC versus anthracycline/taxane-based chemotherapy for high-risk HER2-negative BC
Track 8:
Role of anthracyclines in patients with HER2-positive BC
Track 9:
Case: A 56-year-old woman with ER/PR-positive, HER2-negative invasive lobular BC and bone metastases
Track 10:
Emergence of ESR1 mutations in patients with ER-positive mBC
Track 11:
Clinical significance of ESR1 mutations in patients receiving fulvestrant for ER-positive mBC
Track 12:
Detection of ESR mutations in the plasma of patients with ER-positive BC
Track 13:
CDK4/6 inhibitors as first-line therapy for patients with ER-positive, HER2-negative mBC
Track 14:
Efficacy and tolerability of CDK4/6 inhibitors for patients with ER-positive, HER2-negative mBC
Track 15:
Activity and tolerability of abemaciclib
Track 16:
Case: A 52-year-old woman with a Stage I, ER/PR-negative, HER2-positive, poorly differentiated IDC
Track 17:
APT trial: Results after a 7-year follow-up of adjuvant paclitaxel/trastuzumab for lower-risk, HER2-positive BC
Track 18:
Results of the APHINITY trial evaluating adjuvant pertuzumab
Track 19:
ExteNET: Results of a Phase III trial investigating neratinib after trastuzumab-based adjuvant therapy for patients with HER2-positive BC
Track 20:
ATEMPT: An ongoing Phase II trial evaluating T-DM1 versus trastuzumab/paclitaxel for Stage I, HER2-positive BC
Track 21:
Efficacy of enzalutamide in BC
Track 22:
Case: A 40-year-old woman with mTNBC and a BRCA1 mutation receives olaparib on the OlympiAD trial
FACULTY:
Mark Robson, MD
Clinic Director
Clinical Genetics Service
Associate Attending Physician
Clinical Genetics and
Breast Cancer Medicine
Associate Member
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Medical College of
Cornell University
New York, New York
Ian E Krop, MD, PhD
Director of Clinical Research
Breast Oncology Center
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
EDITOR:
Neil Love, MD
Research To Practice
Miami, Florida